New drug duo tested to fight advanced GI cancers

NCT ID NCT04511039

Summary

This early-stage study aims to find the safest and most effective dose of a new two-drug combination for people with advanced colorectal or gastroesophageal (stomach/esophagus) cancers that have spread. The trial will enroll about 45 adults whose cancer has progressed after at least one prior treatment. Researchers will closely monitor how the drugs work together in the body and look for early signs that the combination can slow tumor growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14263, United States

    Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED MALIGNANT SOLID NEOPLASM CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA CLINICAL STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA A LOCALLY ADVANCED COLORECTAL CARCINOMA LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA METASTATIC COLORECTAL ADENOCARCINOMA METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 STAGE III COLORECTAL CANCER AJCC V8 STAGE IIIA COLORECTAL CANCER AJCC V8 STAGE IIIB COLORECTAL CANCER AJCC V8 STAGE IIIC COLORECTAL CANCER AJCC V8 STAGE IV COLORECTAL CANCER AJCC V8 STAGE IVA COLORECTAL CANCER AJCC V8 STAGE IVB COLORECTAL CANCER AJCC V8 STAGE IVC COLORECTAL CANCER AJCC V8